News

The approval marks the first approved combination and first approved sumatriptan migraine product for patients aged 12-17 years. The company said that the two medicines sumatriptan and naproxen

ALN-AAT is a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT). The company said that ALN-AAT employs its Enhanced Stabilization Chemistry (ESC)-GalNAc delivery technology. The proposed clinical

HS, referred to as acne inversa, is a painful, chronic inflammatory skin disease for which there is no known cure and no approved medication. It is characterized by

The company said that additional site approval comes amid increased industry demand for sterile Intravenous (IV) solutions The approval includes product presentations in 250mL, 500mL and 1000mL, which

The Chinese patent, along with several U.S. patents, cover a novel radiopharmaceutical molecule, which can be used for targeting dead and dying cells associated with cancer, inflammation, and

SanBio developed SB623 to promote regenerative processes in the central nervous system and provide therapeutic options for chronic stroke and other debilitating neurological disorders. United States Patent No.

There are an estimated 9 million Americans suffering from osteoarthritis of the knee, one of the leading causes of disability in the US. As noted by the FDA

The study showed the investigational cancer immunotherapy MPDL3280A (anti-PDL1) doubled the likelihood of survival (overall survival [OS]; HR=0.47) in people whose cancer expressed the highest levels of PD-L1

The study met its primary endpoint of reducing monthly mean migraine days compared with placebo. The data were presented at the 17th Congress of the International Headache Society